# Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis

> **NCT01435993** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 3 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** GSK1223249
- **OTHER:** Saline placebo

## Key facts

- **NCT ID:** NCT01435993
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-09-08
- **Primary completion:** 2012-01-23
- **Final completion:** 2012-01-23
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2020-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01435993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01435993, "Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01435993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*